Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2022

Note 7 - Accounts Payable and Accrued Expenses

At March 31, 2022 and December 31, 2021, accounts payable and accrued expenses consisted of the following ($ in thousands):


	March 31,		December 31,
	2022		2021
Accounts payable	$	9,859	$	16,139
Accrued compensation		339		843
Research and development		11,180		7,704
Other		297		233
Total accounts payable and accrued expenses	$	21,675	$	24,919